

56

JCWSCS 25 MAY 2004

MAY, 24, 2004

1:45PM

TTC-PA 650-326-2422

NO. 780

P. 1/8

PTO/SB/21 (08-03)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/724,953
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
Total Number of Pages In This Submission	8	Attorney Docket Number	1527QJ-005913US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Request for Corrected Filing Receipt (2 pages); marked up copy of Filing Receipt of 2/28/01 (2 pages); Supplemental Application Data Sheet (2 pages); and page 2 of Examiner's Amendment mailed 3/11/04.
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>
Date	May 24, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-746-9195 on May 24, 2004.			
Typed or printed name	Aubrett Baker		
Signature	<i>Aubrett Baker</i>	Date	May 24, 2004

60219861 v1

I hereby certify that this correspondence is being facsimile transmitted to the Patent Office, facsimile number 1-703-746-9195, on May 24, 2004.

By:

Rosemarie L. Celli
Rosemarie L. Celli

PATENT

Attorney Docket No.: 15270J-005913US

Client Ref. No.: 209-US-NEW6C3

Application No.: 09/724,953
Applicant: Dale B. Schenk
Filed: November 28, 2000
TC/A.U.: 1600/1647
Examiner: Christopher J. Nichols

Confirmation No.: 9560

Docket No.: 15270J-005913US
Customer No.: 20350

Office of Initial Patent Examination
United States Patent and Trademark Office

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Issuance of a corrected filing receipt is respectfully requested. Attached hereto is a marked-up copy of the Corrected Filing Receipt mailed by the United States Patent and Trademark Office on February 26, 2001.

Please correct the Domestic Priority data as claimed by applicant. (See attached Supplemental Application Data Sheet filed May 27, 2003 and page 2 of the Amendment filed May 27, 2003; both of which are attached hereto).

Add the following to the existing domestic priority data:

THIS APPLICATION IS ALSO A CON OF 09/585,817 06/01/2000
WHICH IS A CIP OF 09/580,015 05/26/2000
WHICH IS A CIP OF 09/322,289 05/28/1999
WHICH IS A CIP OF 09/201,430 11/30/1998
WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998
AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

Application No. 09/724,567

PATENT

Request for Corrected Filing Receipt of May 24, 2004

Please correct the title. (See page 2 of the Examiner's Amendment mailed March 11, 2004 along with the Notice of Allowance and Issue Fee due).

Methods of Treatment of Alzheimer's Disease

Applicant believes no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the previously noted deposit account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC
60218784 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/724,953	11/28/2000	1647	0	209-US-NEWS6	16	57	5

21835

ELAN PHARMACEUTICALS, INC.
INTELLECTUAL PROPERTY DEPARTMENT
800 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

FILING RECEIPT



000000005802783

Date Mailed: 02/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dale B. Schenk, Burlingame, CA ;

Continuing Data as Claimed by Applicant

~~THIS APPLICATION IS A CON OF 09/585,817 06/01/2000~~
~~WHICH CLAIMS BENEFIT OF 60/137,010 06/~~

Foreign Applications

If Required, Foreign Filing License Granted 02/26/2001

THIS APPLICATION IS ALSO A CON OF 09/585,817 06/01/2000
WHICH IS A CIP OF 09/580,015 05/26/2000
WHICH IS A CIP OF 09/322,289 05/28/1999
WHICH IS A CIP OF 09/201,430 11/30/1998
WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998
AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

Title

~~Pharmaceutical compositions and methods for treatment of amyloid diseases~~

Preliminary Class

424

METHODS OF TREATMENT OF ALZHEIMER'S DISEASE

Data entry by : WYATT, DEBRA

Team : OIPE

Date: 02/26/2001

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Application/Control Number: 09/724,953
Art Unit: 1647

Page 2

DETAILED ACTION

Status of Application, Amendments, and/or Claims

1. As a courtesy to Applicant and upon review of the amendments that have obviated or rendered moot certain rejections, finality is withdrawn and prosecution on the merits is hereby reopened.
2. The Amendment and Response filed 29 December 2003 has been received and entered in full. Claims 1-10, 12, 13, 15, 17, 20, and 26-57 have been cancelled. Claims 59-71 have been added. Claims 11 and 58 have been amended. Claims 11, 14, 16, 18, 19, 21-25, and 58-71 are under examination.
3. All Rejections and Objections not herein maintained are hereby *withdrawn* or *moot* do to amendments.
4. The Terminal Disclaimer filed 11 February 2004 has been received and entered in full.

EXAMINER'S AMENDMENT

5. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

In the Title:

METHODS OF TREATMENT OF ALZHEIMER'S DISEASE